Chantilly, Virginia October 2015
The United States Army Medical Research Institute of Chemical Defense (USAMRICD) is a world leader in the discovery and development of medical products, treatment protocols, and solutions against chemical poisoning and threats through research and development. As the only remaining U.S. facility performing live agent research into the exposure and effects of chemical warfare agents (CWAs), USAMRICD is a key component of our national deterrent and tactical defensive capabilities. Whether it is developing accurate markers and sensitive methods of detecting exposure, evaluating the use of human recombinant PON1 (rePON1) to increase survival to exposure, or investigating adaptive biological responses as potential therapeutic targets to reduce the toxic effects of exposure, USAMRICD research and efforts are crucial not just to the warfighter, but to the American people.
Advancing treatment and countermeasures against chemical agents such as VX, GD, GB, sulfur mustard (HD), other organophosphates, and commercial compounds such as ammonia requires a range of very specific skills and specialties. Edmond Scientific Company (ESC) provides researchers in biology, molecular biology, pharmacology, neuroscience, biochemistry, physiology, and immunology as well as laboratory support staff to help advance USAMRICD’s military mission and the nation’s civil defense preparedness. Among other areas, ESC supports current research in the evaluation of anticholinergic and antiglutamatergic ligands, medical countermeasures to attenuate neuropathological and behavioral consequences, the use of cannabinoids as adjunct to standard therapy, and assessments of treatment strategies for accidental inhalation of industrial chemicals such as ammonia. In addition to advancing protection of U.S. Military Forces and civil defense, some of the research has dual-use in that it is also relevant to treatment of chronic pain, bipolar disorder, and Alzheimer’s.